Commentary

Homing-in on the origin of biliary steroids

The raison d’être of bile is to provide a conduit to eliminate excess cholesterol from the organism. Biliary secretion accomplishes this function in two ways. The liver secretes unesterified (free) cholesterol molecules into bile and also converts cholesterol molecules into bile acids, which are secreted as water soluble anions (bile salts). Bile salt synthesis from cholesterol compensates for obligatory faecal loss (as acidic sterols) during enterohepatic cycling, and this feedback control is regulated by the ecalloss(asacidicsterols)duringenterohepaticcycling,andsynthesisfromcholesterolcompensatesforobligatoryfae-

secreted as water soluble anions (bile salts). Bile salt synthesis from cholesterol compensates for obligatory faecal loss (as acidic sterols) during enterohepatic cycling, and this feedback control is regulated by the efficiency of bile salt return from the intestine. In a healthy human of ideal body weight, de novo synthesis amounts to about 250 mg a day and the bile salt pool, which approximates 3 g, cycles 8 to 12 times a day; therefore, the contribution of bile salt synthesis to biliary secretion is approximately 1%. In contrast to the efficiency of the enterohepatic circulation, 50% of the 1000 mg of cholesterol secreted daily into bile is lost in faeces as bacterial metabolic products (neutral sterols) in faeces, thereby exceeding the loss of cholesterol as acidic sterols by a factor of 2 to 1.

Knowledge of the precursor sources and disposition of biliary cholesterol and bile salts is important for its own sake and to provide targets for new drugs because of the high prevalence rates of atherosclerosis and cholesterol gallstones in Western societies. In both animals and humans, the contributions of de novo cholesterol synthesis to biliary cholesterol secretion, as well as bile salt synthesis, are now considered to be of minor quantitative importance, with estimates as low as 10%. Clearly, the evidence suggests that biliary cholesterol and bile salt molecules derive principally from preformed cholesterol in plasma lipoproteins. Now, Hillebrant and colleagues (see page 700) have narrowed the focus and carried out a difficult and masterful study of patients with cholesterol gallstones with intentional total biliary diversions for about 20% of the mass of cholesterol secreted into bile cholesterol. Although cholesteryl esters in the core of HDL contribute to bile salt synthesis 7, it is not known how much is destined for biliary secretion as free cholesterol. A calculation reveals that HDL’s unesterified cholesterol could only be responsible for about 20% of the mass of cholesterol secreted into bile cholesterol. Although cholesteryl esters in the core of HDL contribute to bile salt synthesis in rats, it is not known how much is destined for bile salt secretion as free cholesterol. A calculation reveals that HDL’s unesterified cholesterol could only be responsible for about 20% of the mass of cholesterol secreted into human bile daily, so based on Hillebrant et al’s study, HDL’s core lipid is a likely contributor. Appropriately, new insights spring from the powerful experimental methods molecular biology and molecular genetics.

It now seems that the hepatic receptor for HDL is the scavenger SR-BI receptor, which acts as a “docking ensemble” binding apolipoprotein AI and holding HDL particles sufficiently long in the space of Disse to allow their cholesteryl esters to enter the hepatocytes by an unknown mechanism. The “empty” HDL particle then continues in the circulation and repeats the uptake of
unesterified cholesterol molecules from peripheral tissues, and their subsequent esterification and delivery to the liver.7 This recycling process from non-hepatic tissues to liver is known as reverse cholesterol transport.4 Recently, using an adenovirus vector, the SR-BI receptor has been overexpressed in murine hepatocytes,10 and the physiological result was the virtual disappearance of plasma HDL, a doubling of biliary cholesterol content, but no change in biliary bile salt concentrations. Obviously, the precise physiological function of this receptor has to be probed by knocking out the mouse gene, which should produce profound hyposcretion of cholesterol, and then doing the rescue experiment by introducing the human SR-BI gene into the knockout animals. In light of this new knowledge, Hillebrant and colleagues’ study comes into perspective, and it seems totally consistent with other work1 emphasizing “…that HDL cholesterol is more related to the biliary secretion of cholesterol than that of bile acids.” All of this presages that HDL concentrations should be related to high cholesterol saturation of bile and prevalence of gallstones—yet the literature suggests an inverse relation between HDL cholesterol, bile cholesterol content, and gallstones.12 15 Nevertheless, seeing that the genetic era of cholesterol gallstone research has dawned,13 perhaps there is a Lith gene that controls the upregulation of the SR-BI receptor and lithogenic bile formation.

In summary, the Hillebrant et al's study supports the concepts that (a) cholesterol molecules carried in the major plasma lipoproteins are the immediate source of both biliary steroids15 and (b) compartmentalisation of lipoprotein cholesterol occurs within the liver with the cholesterol secreted into bile being derived from a pool of cholesterol that is distinct from the one used for bile salt synthesis.4 9 The time seems ripe for unravelling details of these intracellular pools as well as the routes of transhepatic traffic of cholesterol from blood to bile. These pathophysiological concepts support two well known clinical observations of interest to gastroenterologists: with administration of competitive inhibitors (“statins”) of HMG-CoA reductase, the rate limiting enzyme in cholesterol biosynthesis, bile does not become appreciably desaturated simply because of the minor contribution of de novo cholesterol synthesis. As a consequence, cholesterol gallstone dissolution does not seem to occur with these agents. When endogenous bile salt synthesis is profoundly suppressed—for example, with the administration of chenodeoxycholic acid (chenodiol) to attempt oral dissolution of cholesterol gallstones, an appreciable rise in LDL cholesterol concentration ensues. The converse is also the case, in that when faecal bile salt loss is augmented by large doses of cholestyramine or other orally administered binding polymers, by ileal bypass, or by ileal Crohn’s disease, plasma LDL concentrations fall profoundly.